

Attorney Docket No.: MDSP-P02-180

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. **(Currently Amended)** A method for inhibiting reduction of bone density in a mammalian patient having a pathological condition in which bone density is decreased, comprising administering to said patient an effective amount of an anti-IL-11 antibody, which inhibits the formation of a tertiary complex of Interleukin-11 (IL-11), Interleukin-11 receptor (IL-11R), and glycoprotein 130 (gp130), to increase osteoblast-mediated bone formation and to decrease osteoclast-mediated bone resorption, thereby decreasing the rate in loss of bone density in said mammalian patient, wherein said anti-IL-11 antibody inhibits IL-11 signaling pathway in both osteoclasts and osteoblasts.
2. **(Canceled)**
3. **(Previously Presented)** The method of claim 1, wherein the pathological condition is postmenopausal bone loss.
- 4-13. **(Canceled)**
14. **(Previously Presented)** The method of claim 1, wherein said anti-IL-11 antibody is a small molecule no more than 30 kd in molecular weight.
- 15-42. **(Canceled)**
43. **(Previously Presented)** The method of claim 1, wherein said anti-IL-11 antibody is a whole antibody of isotype IgG, IgA, IgM, IgD, or IgE, or a functional fragment thereof which retain an antigen binding site.
44. **(Previously Presented)** The method of claim 1, wherein said anti-IL-11 antibody is a chimeric, hybrid, or genetically engineered antibody, or a functional fragment thereof which retain an antigen binding site.
45. **(Previously Presented)** The method of claim 1, wherein said IL-11 antibody is a proteolytic and/or recombinant fragment, comprising Fab, F(ab')<sub>2</sub>, Fab', Fv, or single chain antibody (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker.

Attorney Docket No.: MDSP-P02-180

46. **(Previously Presented)** The method of claim 1, wherein said IL-11 antibody comprises several scFv covalently or non-covalently linked to form an antibody having two or more binding sites.
47. **(Previously Presented)** The method of claim 1, wherein said IL-11 antibody is a polyclonal antibody.
48. **(Previously Presented)** The method of claim 1, wherein said IL-11 antibody is a purified preparation of antibodies or recombinant antibodies.
49. **(Previously Presented)** The method of claim 1, wherein said IL-11 antibody is a monoclonal antibody.
50. **(Previously Presented)** The method of claim 49, wherein said monoclonal antibody is a humanized monoclonal antibody.